Last reviewed · How we verify
Duloxetine Hydrochloride Capsules
At a glance
| Generic name | Duloxetine Hydrochloride Capsules |
|---|---|
| Also known as | Test Drug |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer (PHASE2, PHASE3)
- Combination of Duloxetine and Pregabalin to Improve Postoperative Pain (PHASE1)
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM) (NA)
- Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy (PHASE3)
- SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine Hydrochloride Capsules CI brief — competitive landscape report
- Duloxetine Hydrochloride Capsules updates RSS · CI watch RSS
- Pfizer portfolio CI